In August, Repligen (NASDAQ:RGEN) decided to get out of the drug discovery business and focus on manufacturing biologic drugs, so it wasn't a big surprise today when the company announced that it had licensed its spinal muscular atrophy, or SMA, program to Pfizer (NYSE:PFE).
The SMA program includes a phase 1 drug candidate, RG3039, as well as backup compounds and enabling technologies. Repligen licensed the program from Families of SMA, a charity that offers support to families and researchers developing drugs to treat the disease. SMA is a neurodegenerative genetic disease that affects approximately one in 6,000 babies.
Repligen will get $5 million upfront and potentially another $65 million if future milestones are met. Pfizer also owes Repligen undisclosed royalties on any future sales of SMA drugs developed under the agreement.
Repligen will complete the first two cohorts of healthy volunteers in the ongoing phase I trial of RG3039, and then Pfizer will take over development of the program.
Fool contributor Brian Orelli has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The 3 Best Dow Dividend Stocks for 2018
Look for these companies to lift the market in the coming year.
3 Top Stocks That Are Cash Cows
It's not just the cash. It's what these companies do with it that really matters.
Why 2017 Was a Year to Forget for Pfizer Inc.
Pfizer's 2017 wasn't horrible. Just ho-hum.